BIOSCI CONSULTING BVBA

Their core work

BioSci Consulting is a Belgian SME specializing in preclinical and nonclinical consulting for the life sciences sector, with deep expertise in safety assessment, immunology, and regulatory science. They provide scientific consulting on topics ranging from toxicology and immune safety modeling to advanced therapy medicinal products (ATMPs) and AI-driven clinical decision support. Their work bridges the gap between laboratory research and clinical translation, helping consortia navigate the complex path from preclinical models to patient-ready therapies.

What they specialise in

How they've shifted over time

BioSci Consulting entered H2020 with a focus on nonclinical assessment — toxicology, immune safety modeling, and neurodevelopmental biomarker research (AIMS-2-TRIALS, imSAVAR). From 2020 onward, their involvement shifted toward translational and patient-facing applications: AI-driven clinical decision support in DRAGON and manufacturing-ready cell therapies in T2EVOLVE. The trajectory shows a clear move from upstream safety science toward downstream therapy development and digital health tools.

BioSci is moving from preclinical consulting toward the translational frontier — expect them to seek roles in projects combining advanced therapies with digital tools and regulatory innovation.

How they like to work

BioSci operates exclusively as a participant, never coordinating — typical for a specialized consulting SME that contributes focused expertise rather than managing large consortia. With 124 unique partners across 17 countries in just 4 projects, they consistently join large-scale Research and Innovation Actions (all projects are RIA), indicating comfort working within big, multi-national teams. Their value proposition is niche scientific input, not project management.

Despite only 4 projects, BioSci has collaborated with 124 unique partners across 17 countries, reflecting participation in large flagship-style consortia. Their network spans most of Western and Central Europe, with strong exposure to major research hospitals and pharma networks.

What sets them apart

BioSci Consulting sits at a rare intersection: preclinical safety science, computational immunology, and advanced therapy consulting — all within a small, agile SME structure. Unlike large CROs, they can embed flexibly in academic-led consortia while providing industry-grade regulatory and nonclinical expertise. For consortium builders, they offer the depth of a specialist without the overhead of a large corporate partner.

Highlights from their portfolio

• DRAGON
  Largest single grant (EUR 505,000) and a thematic outlier — applying AI and deep learning to pandemic precision medicine, signaling BioSci's expansion into digital health.
• T2EVOLVE
  Significant funding (EUR 476,000) in the high-growth CAR-T/TCR cell therapy space, covering the full chain from genetic engineering to GMP manufacturing and patient access.
• imSAVAR
  Core to BioSci's identity — immune safety assessment using micro physiological systems and computational immunology, representing their foundational nonclinical expertise.